Eχει κατατεθει η πατεντα στις ΗΠΑ ενος συστηματος το οποιο θα αποθηκευει τις ηλεκτρονικες ταυτοτητες ατομων που εχουν εμβολιαστει σε εναν σερβερ και θα μπορει να παρακολουθει που βρισκονται συνεχως,αυτο ειναι το επομενο βημα της μεγαλης επανεκκινησης,της Νεας ταξης πραγματων,της Παγκοσμιας κυβερνησης,δεν κρυβονται πλεον,θελουν πληρως ελεγχομενο τον ανθρωπο,αυτο απανταει και στο ερωτημα ....αφου τα εμβολια δεν προστατευουν απο τον κορωνοιο γιατι ολες οι κυβερνησεις θελουν να εμβολιασουν οσο περισσοτερους ανθρωπους μπορουν?
Ο Θεος βοηθος με τους Σαταναδες που μπλεξαμε,ποιος ξερει τι αλλο σχεδιαζουν.
System and methods for anonymously selecting subjects for treatment against an infectious disease caused by a pathogen. The system comprises a plurality of electronic devices comprising instructions to generate an ID and, when in proximity of another such electronic device, one or both electronic devices transmit/receive the ID to/from the other electronic device. Then, a score is generated based on a plurality of such received IDs. Additionally, based on information received from a server, relevant treatment instructions are displayed to the subjects based on the received information and the score. The server comprises instructions for sending to the plurality of electronic devices the information to be displayed with the relevant treatment instructions, additionally the server and/or the electronic devices comprise instructions to generate a prediction of likelihood of a subject transmitting the pathogen, based on the score of the subject.
This application claims the benefit of priority of Israel Patent Application No. 277083 filed on Sep. 1, 2020, Israel Patent Application No. 276665 filed on Aug. 11, 2020, and Israel Patent Application No. 276648 filed on Aug. 11, 2020. The contents of the above applications are all incorporated by reference as if fully set forth herein in their entirety.
This application is also related to United Arab Emirates Patent Application No. P6001304/2020 filed on Sep. 17, 2020, the contents of which are incorporated herein by reference in their entirety.
FIELD AND BACKGROUND OF THE INVENTIONThe present invention, in some embodiments thereof, relates to methods and systems of prioritizing vaccinations\treatments\testing and, more particularly, but not exclusively, to method and systems of prioritizing vaccinations\treatments\testing in a pandemic situation, whereby vaccines are at short supply and while protecting the privacy of the individuals in the population.
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified in December 2019 in Wuhan, Hubei, China, and has resulted in an ongoing pandemic. The first confirmed case has been traced back to 17 Nov. 2019 in Hubei. As of 6 August 2020, more than 18.7 million cases have been reported across 188 countries and territories, resulting in more than 706,000 deaths. More than 11.3 million people have recovered. The virus is primarily spread between people during close contact, most often via small droplets produced by coughing, sneezing, and talking. The droplets usually fall to the ground or onto surfaces rather than travelling through air over long distances. However, the transmission may also occur through smaller droplets that are able to stay suspended in the air for longer periods of time in enclosed spaces, as typical for airborne diseases. Less commonly, people may become infected by touching a contaminated surface and then touching their face. It is most contagious during the first three days after the onset of symptoms, although spread is possible before symptoms appear, after they disappear and from people who show very mild or do not show symptoms at all.
In addition, about 5% of COVID-19 patients experience complications including septic shock, acute respiratory distress syndrome (ARDS), acute cardiac or kidney injury, and disseminated intravascular coagulation (DIC). These complications are thought to be manifestations of the cytokine storm triggered by the host immune response of the virus. In critically ill patients, ARDS was the most common complication in 67% of the patients with a 28-day mortality of 61.5%. DIC has been widely reported in COVID-19. Pulmonary embolism (PE) in COVID-19 patients has been reported in a few studies. A recent study pointed to a higher incidence of PE with 23% in severe COVID-19 patients. The relationship between virally triggered inflammation, venous thromboembolism, and ARDS in COVID-19 is still under investigation. Given that patients with severe COVID-19 often present with shortness of breath and pulmonary infiltrates, the diagnosis of PE may be overlooked in the context of an ARDS diagnosis.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου